Articles

• FDA Approves Keytruda for First-Line Treatment of Non–Small-Cell Lung Cancer (TPS ≥1%)
• FDA Advises Women to Avoid Pregnancy for Only 2 Months After Final Dose of Soltamox

Read More ›

Read More ›

On April 4, 2019, the US Food and Drug Administration (FDA) expanded the indication of palbociclib (Ibrance; Pfizer), a kinase inhibitor, in combination with specific endocrine therapies for men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This is the first hormonal-based therapy to be approved for men. Read More ›

On March 27, 2019, the US Food and Drug Administration (FDA) issued an alert from its Office of Women’s Health announcing that, after more than 20 years of regulatory oversight, the agency is proposing amendments to the existing policy governing mammography services. Read More ›

For the second time this month, the FDA has given an approval to Genentech’s PD-L1 inhibitor, Tecentriq. Read More ›

Following the advent of molecularly targeted agents, and more recently, immunotherapy, over the past few decades, we have witnessed dramatic changes in the treatment paradigms for many types of cancer. Read More ›

The clinical application of assays that utilize next-generation sequencing (NGS) technology is accelerating rapidly in the field of oncology. Read More ›

The advent of next-generation sequencing (NGS) technologies has revolutionized the way we approach and utilize molecular diagnostic testing in oncology. Read More ›

The advent of next-generation sequencing (NGS) technologies has revolutionized the way we approach and utilize molecular diagnostic testing in oncology. Read More ›

The clinical application of assays that utilize next-generation sequencing (NGS) technology is accelerating rapidly in the field of oncology. Read More ›